Cancer Care

 

 
ACCL0933 A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Principal Investigator (?)
Study Number
ACCL0933
Summary
This randomized phase III clinical trial is studying caspofungin acetate to see how it works
compared to fluconazole in preventing invasive fungal infections in patients with acute
myeloid leukemia who are undergoing chemotherapy. Caspofungin acetate or fluconazole may
help prevent fungal infections caused by chemotherapy. It is not yet known whether
fluconazole is more effective than caspofungin acetate in preventing fungal infections in
patients with acute myeloid leukemia who are undergoing chemotherapy.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Lebanon

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.